Clinical Trials Browser

Phase 1/2 × Unknown × Dacarbazine × Clear all

NCT02076646 2022-04-14

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Phase 1/2 Unknown

Melanoma, Neoplasm Metastasis